Entities / Company
Cidara Therapeutics.
company in San Diego, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
RBC boosted the price target for Cidara Therapeutics to $75.Speculative1 report
-
Cidara Therapeutics filed an offering with the U.S. Securities and Exchange Commission, with Morgan Stanley and Cantor acting as joint book-running managers.Speculative3 reports
-
Cidara Therapeutics was included in the Russell 2000 and 3000 indexes on June 30, 2025.Speculative1 report
-
Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.Some support8 reports
No events began in the chosen period. Widen it, or reset.
Around Cidara Therapeutics this week
News at the entities that move Cidara Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Cidara Therapeutics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Cidara Therapeutics
-
Merck StructuralEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Cidara Therapeutics
-
Morgan Stanley TransactionalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Cidara Therapeutics
-
San Diego Shared contextLegal challenges are underway regarding San Diego's city policy on street vending, with an advocate speaking on behalf of Gaslamp Quarter businesses.Moves Cidara Therapeutics
Connections
The 6 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Cidara Therapeutics is subject to formal regulatory requirements and filing mandates imposed by the SEC.
-
FDA Structural
The FDA provides formal regulatory oversight and grants designations for Cidara Therapeutics' drug development.
-
Merck Structural
Merck acquired Cidara Therapeutics, establishing a current parent-subsidiary relationship.
-
MRK Operational
The relationship is characterized by active market competition, discussed alongside peer groups.
-
Morgan Stanley Transactional
Morgan Stanley served as the joint book-running manager for Cidara Therapeutics during a financing event.
-
San Diego Shared context
Cidara Therapeutics is headquartered in San Diego.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
4 events- RBC boosted the price target for Cidara Therapeutics to $75.
- Cidara Therapeutics filed an offering with the U.S. Securities and Exchange Commission, with Morgan Stanley and Cantor acting as joint book-running managers.
- Cidara Therapeutics was included in the Russell 2000 and 3000 indexes on June 30, 2025.
- Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.